Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 41 pages report, published by Global Markets Direct

Keywords : Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Therapeutic Products under Development, Key Players in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Therapeutics, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline Overview, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline, Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) Pipeline Assessment

Report ThumbnailJune-2017
Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2017'; Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways.

The report 'Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Cardiovascular, Central Nervous System, Musculoskeletal Disorders and Oncology which include indications Rheumatoid Arthritis, Inflammation, Gouty Arthritis (Gout), Metastatic Breast Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Ductal Adenocarcinoma and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
- The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
  • Pipeline by ProteoThera Inc, H1 2017
  • Pipeline by Swedish Orphan Biovitrum AB, H1 2017
  • Pipeline by XL-protein GmbH, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
  • Paras Biopharmaceuticals Finland Oy
  • ProteoThera Inc
  • Swedish Orphan Biovitrum AB
  • XL-protein GmbH
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
  • anakinra - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • anakinra biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL1R1 for Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRT-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-130 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
  • Featured News & Press Releases
  • May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
  • Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
  • Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
  • Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
  • Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
  • Apr 23, 2014: First treatment for babies with ultra-rare spectrum of autoinflammatory diseases now available in UK
  • Dec 06, 2013: First treatment for infants with ultra-rare spectrum of autoinflammatory diseases licensed in UK
  • Sep 19, 2013: Swedish Orphan Biovitrum Receives CHMP Positive Opinion For Treatment Of Cryopyrin-Associated Periodic Syndrome
  • Jun 11, 2013: Sobi Gets FDA Approval To Manufacture Substance For Kineret With Partner Boehringer Ingelheim
  • Apr 18, 2013: Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease, Study Finds
  • Jan 23, 2013: Sobi Receives EMA Approval To Manufacture Kineret Drug Substance With Partner Boehringer Ingelheim
  • Jan 08, 2013: Sobi's Kineret Receives FDA Approval For Treatment Of Neonatal-onset Multisystem Inflammatory Disease
  • Nov 19, 2012: Sobi Files To Expand Kineret Label To Include CAPS
  • Jul 06, 2012: Sobi Files For NOMID Indication For Kineret In US
  • Aug 26, 2010: Swedish Orphan Biovitrum Receives FDA Orphan Drug Designation For Kineret
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectInterleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017Product ThumbnailInterleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2017, Industry ReportProduct #: 829027
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved